Platelet Factor 4 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Platelet Factor 4 is a protein released by the tiny cells that help blood clot. In 2023, three separate labs reported it restored memory in old mice. There is more of it in young human blood than old, and it has never been given to a person.
Evidence grade for Platelet Factor 4: Animal or lab only. The rule: only animal or lab studies on this page. No study in people yet. The sum on this page: 3 animal studies, no human study. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
3 animal studies, no human study
4 effects reported, 4 unwanted, by people using it, not a trial
Goal pages: Brain, memory and mood
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is a protein released by platelets, the tiny cells that help blood clot. In 2023, three separate labs reported it restored memory in old mice, within one month of each other.
What people take it for
- Memory and brain ageing.
- The benefits of exercise, since one lab called it an exercise factor.
What studies in people showed
Nobody has been given this and no trial is registered. In people, all we have is a measurement. There is more of it in young blood than old. In mice, old animals got a platelet rich part of young plasma. It calmed swelling in the memory centre and improved memory. Giving the protein alone did the same. Three labs got the same answer at the same time. That is the best signal animal work gives. It is still animal work. The one thing well known about this protein in people is a warning. Stuck to the blood thinner heparin, it can set off a bad clotting problem.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- In people, this protein's best known role is a dangerous immune clotting reaction.
- Nobody has given it to a person, so there is no safety data.
- Three years after three big papers, no company has registered a trial. That silence is a signal.
- All three papers are mouse studies, however famous the journals.
Where these come from: The mouse results and the clotting disorder review come from the studies on this page. No user reports exist.
My bottom line
Three labs agreeing is the best animal signal you will see. The clotting problem in people is why nobody has moved.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Memory and thinking2 animal or lab studies
35 of the 36 indexed goals have no study of any kind behind Platelet Factor 4
No study in people, animals or cells on this page reports a result for these. That does not prove Platelet Factor 4 does nothing for them. It does mean anything you have heard about Platelet Factor 4 and one of these did not come from a study cited here.
Show full evidence
What is Platelet Factor 4?
Platelet Factor 4 is a protein released by the tiny cells that help blood clot. In 2023, three separate labs reported it restored memory in old mice. There is more of it in young human blood than old, and it has never been given to a person.
Nobody has been given PF4 as a treatment, and no trial is registered.
The human part of this is a measurement. There is more PF4 in the blood of young people than older ones, alongside the same finding in mice.
PF4 does have a big human medical record, and it is worth knowing, because it is a warning rather than a support. PF4 is the target in a condition called heparin-induced thrombocytopenia. The immune system makes antibodies against PF4 stuck to the blood thinner heparin. Those antibodies switch on the clot-forming cells and cause dangerous clots. So anything that raises PF4 in a person is walking into the area where this protein's best documented human role is immune-driven clotting.
In August 2023, three separate groups published in Nature Communications, Nature and Nature Aging within a month of each other. All landed on the same molecule. Platelet factor 4, also called CXCL4, is released by platelets, the tiny cells that help blood clot. In mice, giving old animals a platelet-rich part of young mouse plasma calmed inflammation in the memory centre of the brain and improved their memory. Giving PF4 on its own did the same. One group called it an exercise factor. One called it a young blood factor. One placed it downstream of klotho, a longevity protein this site covers separately. The Nature paper points at a receptor called CXCR3 as carrying part of the benefit.
Three labs landing on the same answer at the same time is unusual, and it is the strongest thing about this work. What it does not do is make any of it human. All three papers are mouse studies.
How does Platelet Factor 4 work?
In mice, PF4 given through the body calms age-related inflammation in the memory centre of the brain, at the level of both gene activity and cells. It produces changes linked to brain connections adapting, and it improves memory. A receptor called CXCR3 carries part of that effect, and restoring the ageing immune system outside the brain seems to be involved too. One of the 2023 papers puts PF4 downstream of klotho. In people, the known biology is about clotting and the immune system. PF4 is released from packets inside platelets. It sticks to heparin and similar sugars. PF4 stuck to heparin is what the immune system attacks in heparin-induced thrombocytopenia. No effect on memory has been shown in a person.
What have studies in people found about Platelet Factor 4?
None as a treatment. Nobody has received platelet factor 4. The human data are a measurement, that there is more PF4 in young people's blood than older people's, plus a large medical record of PF4 as the target in a heparin-triggered clotting disorder. That is about clots, not memory.
- The 2023 Nature paper reports more PF4 in blood plasma from young people than from older ones, alongside the same finding in mice. That is a measurement in human samples, not a treatment.
- We could find no registered trial giving PF4 to people for memory, ageing or anything else.
- PF4's known role in people is as the target in heparin-induced thrombocytopenia. Antibodies against PF4 stuck to heparin switch on the clot-forming cells and cause dangerous clots. This is a well described human condition, and it is the main reason giving PF4 to people is not a simple idea.
What this does not tell you: Three mouse papers pointing the same way do not make a human finding. Nothing is known about whether PF4 given to a person improves memory. And the one thing well established about PF4 in people is a harmful immune reaction involving it. Any programme in people would have to deal with that head on, and none has been registered.
The state of the research
Three separate labs published PF4 papers in the same month, August 2023, in Nature, Nature Communications and Nature Aging. That is the most convincing thing about this molecule. When separate labs land on the same answer without coordinating, that is the strongest signal animal research produces, and it counts for more than any one paper, however famous the journal. It is also a reason to expect somebody to ask the human question. Three years on, nobody has.
The likely reason sits in the human record, not the mouse record. In people, PF4's known role is as the target in a serious clotting disorder triggered by heparin. Giving a healthy older adult PF4 to improve memory would mean raising a protein whose main claim to fame in people is a dangerous immune clotting reaction. No company has registered a trial that takes that on.
The klotho link is worth following for readers of this site, because klotho has its own page and its own programme in people. One of the 2023 papers puts platelet factors downstream of klotho. If that holds, PF4 would be part of how klotho works, rather than a target in its own right.
The evidence, in charts
Fig. 1a · how many people
0people have taken this in any study cited here
0 people · 0 studies in people
What this page cites instead is 3 animal studies and 1 review. None of them gave the compound to a person.
Counted from the list of sources on this page. We draw this chart only when a study in people is cited. An empty one is the answer, not a gap in the page.
Fig. 1b · evidence mix
None of the 4 sources here are studies in people.
- Animal study · done in animals375%
- Review of studies · sums up other studies125%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2017 and 2023.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Biologic
- Molecule weight
- Not on file
- Half-life
- None on file
- Chain length
- None on file
No amino acid sequence is on file for Platelet Factor 4, so none is drawn rather than guessed from a name.
The studies we cite
- Review of studies2017Heparin-induced thrombocytopenia
A medical review of heparin-induced thrombocytopenia, a condition in people. Antibodies against platelet factor 4 stuck to the blood thinner heparin switch on the clot-forming cells and cause dangerous clots. This is the setting in which PF4 is measured in people, and it is why its human record is a warning rather than a support. It is not an ageing study.
Human clinical review of heparin-induced thrombocytopenia, the condition in which antibodies to complexes of platelet factor 4 and heparin activate platelets and cause thrombosis. This is the context in which PF4 is measured in people and the reason its human profile is a caution rather than a support. It is not an ageing study.
- Animal study2023Platelet factors attenuate inflammation and rescue cognition in ageing
In old male mice, a platelet-rich part of young mouse plasma calmed inflammation in the memory centre of the brain and improved memory. There was more of the protein PF4 in blood from young mice and young people than from older ones. Giving PF4 on its own did the same job in old mice: less inflammation in the memory centre, better memory. A receptor called CXCR3 carries part of the effect. Funded by the US National Institutes of Health.
Mouse. Systemic exposure of aged male mice to a platelet-containing fraction of young mouse plasma decreased hippocampal neuroinflammation at transcriptional and cellular levels and improved hippocampal-dependent cognition. Circulating PF4 was elevated in plasma preparations of young mice and young humans relative to older individuals. Systemic PF4 alone attenuated age-related hippocampal neuroinflammation and improved cognition in aged mice, with CXCR3 identified as partly mediating the effect. NIH funded.
- Animal study2023Platelet-derived exerkine CXCL4/platelet factor 4 rejuvenates hippocampal neurogenesis and restores cognitive function in aged mice
In mice, PF4 is described as a protein released during exercise. It restored the growth of new brain cells in the memory centre and brought back memory in old mice. This is one of three papers from separate labs, published within a month, that reached the same conclusion. Funded by the US National Institutes of Health with other support.
Mouse. PF4 characterised as an exercise-released factor that rejuvenates hippocampal neurogenesis and restores cognitive function in aged mice. One of three independent papers published within a month reaching a convergent conclusion. NIH funded with non-US government support.
- Animal study2023Platelet factors are induced by longevity factor klotho and enhance cognition in young and aging mice
In mice, klotho switches on platelet factors including PF4, and those factors improved memory in both young and ageing animals. That puts PF4 downstream of a longevity protein this site covers on its own page. Funded by the US National Institutes of Health.
Mouse. Platelet factors including PF4 are induced by klotho and enhance cognition in both young and ageing mice, placing PF4 downstream of a longevity protein this site covers separately. NIH funded.
Common questions
Has Platelet Factor 4 been tested in people?
Not in any study cited here. Platelet Factor 4 is a protein released by the tiny cells that help blood clot. In 2023, three separate labs reported it restored memory in old mice. There is more of it in young human blood than old, and it has never been given to a person.
What is the Platelet Factor 4 dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 3 animal studies, no human study
Is Platelet Factor 4 FDA-approved?
Not approved as a treatment, and never given to a person. In medicine, PF4 is what a lab test measures to check for heparin-induced thrombocytopenia, a drop in platelets caused by the blood thinner heparin. That is a test, not a treatment.
Has PF4 been given to a human?
No. Nobody has been given platelet factor 4 for memory, ageing or anything else, and no trial is registered. The three 2023 papers that caused the excitement are all mouse studies.
Why did three papers appear at once?
Three separate labs landed on the same molecule and published in Nature, Nature Communications and Nature Aging within a month in August 2023. One called it a young blood factor, one an exercise factor, one a factor switched on by klotho. Separate labs agreeing is the strongest kind of signal animal research produces. It is still animal research.
Is raising PF4 risky?
It has not been tested in a person, so there is no direct answer. What is established in people is that antibodies against PF4 stuck to heparin cause heparin-induced thrombocytopenia, a serious clotting disorder. That is the role of this protein with the biggest medical record behind it, and it is the first question any programme in people would have to answer.
How does this relate to klotho?
One of the 2023 papers, in Nature Aging, found that klotho switches on platelet factors including PF4, and that those factors improved memory in young and old mice. If that holds, PF4 would be part of how klotho works rather than a target on its own. Klotho has its own page on this site, with its own programme in people.